Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
|Active Ingredient:||Ocrelizumab 300mg|
|Dosage Form:||Concentrate for infusion|
|New Zealand Sponsor:||Roche Products (NZ) Limited|
|Manufacturers:||Roche Diagnostics GmbH, Mannheim, Germany
F. Hoffmann-La Roche AG, Kaiseraugst, Switzerland
Dated this 20th day of November 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).